BioRestorative Therapies Closes Public Offering, Raises $5 Million
MELVILLE, N.Y. — February 13, 2026 — Leads & Copy —
BioRestorative Therapies, Inc. (NASDAQ:BRTX) has announced the closing of its public offering, raising approximately $5.0 million before deducting fees and expenses.
The regenerative medicine innovator offered 14,285,715 shares of common stock (or pre-funded warrants) along with warrants to purchase an equal number of shares. The combined public offering price was $0.35 per share (or pre-funded warrant) and accompanying warrants.
The warrants are immediately exercisable at $0.35 per share and will expire five years from the issuance date.
Rodman & Renshaw LLC served as the exclusive placement agent for the offering.
BioRestorative intends to allocate the net proceeds to fund clinical trials for BRTX-100, pre-clinical research and development of its ThermoStem Program, the development of its commercial biocosmeceuticals platform, and for general corporate purposes and working capital.
The Securities and Exchange Commission (SEC) declared the registration statement on Form S-1, as amended (File No. 333-293322), effective on February 11, 2026. The offering was conducted through a prospectus, available on the SEC’s website and from Rodman & Renshaw LLC.
BioRestorative Therapies, Inc. focuses on cell and tissue protocols, primarily using adult stem cells. The company’s core clinical development programs target disc/spine disease and metabolic disorders, and it also operates a commercial BioCosmeceutical platform.
BRTX-100, the lead cell therapy candidate, is formulated from a patient’s own cultured mesenchymal stem cells collected from bone marrow. It is intended for non-surgical treatment of painful lumbosacral disc disorders or as a complement to surgery. A Phase 2 clinical trial is underway to treat chronic lower back pain from degenerative disc disease, and the FDA has cleared BRTX-100 for evaluation in treating chronic cervical discogenic pain.
The ThermoStem® program is developing cell-based therapy candidates targeting obesity and metabolic disorders, using brown adipose (fat) derived stem cells (BADSC) to generate brown adipose tissue (BAT). Preclinical research suggests that increased brown fat may increase caloric burning and reduce glucose and lipid levels. BADSC secreted exosomes may also impact weight loss.
BioRestorative also operates a commercial BioCosmeceutical platform, producing a cell-based secretome containing exosomes, proteins, and growth factors engineered to reduce the appearance of fine lines and wrinkles. The company intends to expand its offering to include a broader range of cell-based biologic aesthetic products and therapeutics, pursuing FDA approvals in the BioCosmeceuticals space.
Source: BioRestorative Therapies, Inc.
Share this story:
